Rigid gas permeable lens highly influences the interpretation of CXL results

Article

Wearing a rigid gas permeable lens can lead to improved topographic parameters and can significantly alter a number of study parameters.

Wearing a rigid gas permeable lens can lead to improved topographic parameters and can significantly alter a number of study parameters, claims a paper published in the British Journal of Ophthalmology.

A prospective, non-comparative study led by Dr Koppen Carina, Department of Ophthalmology, Antwerp University Hospital, Belgium, comprised of 15 eyes without rigid gas permeable contact lens (CL) and 12 eyes fitted with a CL from 1 to 10 weeks after ultraviolet A/riboflavin cross-linking (CXL) for the stabilisation of progressive keratoconus.

Refractive sphere and cylinder, maximal keratometry value (K max), simulated keratometry steep, flat, astigmatism, refractive power (RP) steep, flat and astigmatism, I-S value on EyeSys, K max on Pentacam and change from baseline of best spectacle-corrected visual acuity (BSCVA) were all used to measure the effect of CXL treatment on patients. The results of the study were recorded pre-CXL and in 6 month intervals for 18 months post-CXL.

There were no study parameters that demonstrated a significant change from baseline results in eyes without CL.

However, in eyes fitted with CL post-CXL I-S value and K max on EyeSys at all time intervals, RP steep and simulated astigmatism at 6 and 12 months and RP flat at 12 months all showed significant improvement.

CL can greatly influence the interpretation of CXL results, with lens wear improving topographic parameters.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.